Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pluristem Therapeutics Inc (NASDAQ:PSTI)

1.49
Delayed Data
As of Jul 28
 -0.02 / -1.32%
Today’s Change
0.71
Today|||52-Week Range
2.45
+31.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$121.0M

Company Description

Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development. It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others. Its products include PLacental eXpanded, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Contact Information

Pluristem Therapeutics, Inc.
MATAM Advanced Technology Park
Haifa Haifa 31905
P:972747108600
Investor Relations:
972747108721

Employees

Shareholders

Individual stakeholders8.29%
Other institutional3.55%
Mutual fund holders1.31%

Top Executives

Zami AbermanChairman & Chief Executive Officer
Yaky YanayPresident, COO, CFO, Secretary & Director
Esther Lukasiewicz-HagaiVice President-Clinical & Medical Affairs
Racheli OfirVice President-Research & Intellectual Property
Hillit Mannor ShacharVice President-Business Development